hygroton k tablet - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

hygroton 25 tablets

amdipharm mercury australia pty ltd - chlortalidone, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; iron oxide red; colloidal anhydrous silica; lactose monohydrate; maize starch; magnesium stearate - indications as at 19 november 1996: essential arterial hypertension, as long as creatinine clearance is >30 ml/min; as primary therapy or in combination with other antihypertensive agents; stable, chronic heart failure of mild to moderate degree (functional class ii, iii), as long as creatinine clearance is >30ml/min; ascites due to cirrhosis of the liver in stable patients under close control.

New Zealand - English - Medsafe (Medicines Safety Authority)

hygroton

aft pharmaceuticals ltd - chlortalidone 25mg; - tablet - 25 mg - active: chlortalidone 25mg excipient: colloidal silicon dioxide iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch purified talc - arterial hypertension, essential or nephrogenic or isolated systolic, as primary therapy or in combination with other antihypertensive agents. stable, chronic heart failure of mild to moderate degree (new york heart association, nhya: functional class ii or iii). - oedema of specific origin - oedema due to peripheral (chronic) venous insufficiency; short-term therapy if physical measures prove insufficient. - fluid retention in premenstrual syndrome only if the gain in weight is the main symptom and is well documented. - ascites due to cirrhosis of the liver in stable patients under close control. - oedema due to nephrotic syndrome. - prophylaxis against recurrent calcium oxalate calculi in patients with idiopathic, normocalcaemic hypercalciuria.